Home › FDA Approves Mercks NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use
 

Keywords :   


FDA Approves Mercks NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use

2014-03-14 18:40:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. Mercks antifungal agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension. Language: English Contact: MerckMedia:Pam Eisele, (267) 305-3558Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: use injection fda approves

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Storm Surge Watch/Warning Map
05.07Tropical Storm Beryl Graphics
05.07Tropical Storm Beryl Forecast Discussion Number 29
05.07Tropical Storm Beryl Wind Speed Probabilities Number 29
05.07Tropical Storm Beryl Forecast Advisory Number 29
05.07Tropical Storm Beryl Public Advisory Number 29
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Tropical Depression Aletta Graphics
More »